Introduction

Hepatitis C virus (HCV) infection has been associated with excess iron deposition in the liver (1, 2). Iron is essential but potently toxic by generating hydroxyl radicals through the Fenton reaction. It has recently been suggested that iron-related oxidative stress may play a role in the pathological mechanisms in chronic hepatitis C (CHC) (2, 3). Several investigators have demonstrated that iron reduction via therapeutic phlebotomy leads to improvements in serum aminotransferase levels in CHC patients
.
However, we found few studies which examined the effect of dietary iron reduction on CHC patients. The aims of this randomized, controlled study were to examine whether or not dietary iron restriction improves serum aminotransferase activities and to compare the efficacy of dietary iron reduction with that of phlebotomy in CHC patients.
PCR) (7) . All patients were hepatitis B surface antigen (HBsAg) Fig. 2) . The statistical analysis in Fig. 1 was performed 
Results
Patient demographics
The clinical, laboratory and demographic features of the patients in the 2 treatment groups at enrollment were comparable (Table 1) 
Changes in laboratory parameters
In treatment A group, sixteen (80%) of 20 patients had decreased serum ALT ( Fig. 2A) 
F i g u r e 1 . S e r u m a l a n i n e a mi n o t r a n s f e r a s e ( AL T ) l e v e l s b e f o r e a n d a f t e r a 6 -mo n t h c o u r s e o f d i et a r y i r o n r e d u c t i o n ( A) o r p h l e b o t o my ( B ) . T h e s i g n i f i c a n c e o f d i f f e r e n c e b e t we e n b e f o r e a n d a f t e r e a c h t r e a t me n t wa s a n a l y z e d b y u s i n g Wi l c o x o n s i g n e d
-r a n k t e s t : * p = 0 . 0 0 2 , * * p < 0 . 0 0 0 1 , c o mp a r e d t o b e f o r e t h e t r e a t me n t . (Fig. 2) . A larger decrease in serum ALT was obtained in treatment B group than in treatment A group (p=0.0007).
T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s o f S t u d y P a t i e n t s a t E n r o l l me n t jects than in group A subjects (p<0.0001). Platelet count did not change in Group
Correlations between percent change in serum alanine aminotransferase level and clinical parameters
In group A subjects, no correlations between percent change in serum ALT and clinical parameters were found F i g u r e 2 . P e r c e n t c h a n g e i n a l a n i n e a mi n o t r a n s f e r a s e
( AL T ) v a l u e f o l l o wi n g p h l e b o t o my t o p a t i e n t s wi t h c h r o n i c h e p a t i t i s o r l i v e r c i r r h o s i s , t y p e C. T h e b o x c o mp r i s e s t h e v a l -
u e s b e t we e n t h e 2 5 t h a n d 7 5 t h p e r c e n t i l e s a n d t h e b o l d h o r iz o n t a l l i n e i s t h e me d i a n ; a n d t h e e r r o r b a r s s t r e t c h f r o m t h e 1 0 t h a n d t o t h e 9 0 t h p e r c e n t i l e . T h e s i g n i f i c a n c e o f d i f f e r e n c e b e t we e n t r e a t me n t A a n d B g r o u p wa s d e t e r mi n e d b y u s i n g Ma n n -Wh i t n e y U a n a l y s i s : * p = 0 . 0 0 0 7 , c o mp a r e d t o t r e a tme n t A.
T a b l e 2 . Co r r e l a t i o n b e t we e n P e r c e n t Ch a n g e i n Al a n i n e Ami n o t r a n s f e r a s e ( AL T ) a n d Cl i n i c a l P a r a me t e r s i n T r e a t me n t A a n d B Gr o u p s (Fig. 2) (12) . In contrast, phlebotomy showed few harmful side effects, as shown in the present study. Therefore, the administration of deferoxamine is not recommended except for HCV-infected patients with hematological disorders such as thalassemia. (Fig. 1) . Similar to our findings, a recent study from India (14) has shown that a lowiron diet for 4 months led to significant reductions in both transaminase activities and iron parameters in patients with hepatitis B-or C-related chronic liver diseases. Though (17, 20, 21 
(Table 2). In group B subjects, only the baseline level of serum ALT was significantly correlated with percent change in serum ALT (p=0.033). We could not detect a relationship between percent change in ALT and the baseline level of serum ferrtin, percent change in serum ferritin, total volume of blood removed by phlebotomy or the amount of total iron removed by phlebotomy. In both group A and B subjects, there were no sex differences in percent change in serum ALT (p=0.760 and p=0.850, respectively).
Side effects
No significant change in weight after completion of the therapy was seen in any of the subjects included in the study. All the patients complied with the dietary regimens, and no adverse effects were observed in the treatment A group. Phlebotomy therapy was well tolerated by all 20 patients in the treatment B group. However, one patient (5%) complained of palpitation on effort, and two patients (10%) experienced transient blindness after one session of phlebotomy.
Discussion
Several previous studies confirmed that phlebotomy significantly reduces transaminase activities in HCV-infected patients (1, 4-6). This randomized control trial clearly demonstrates that iron removal by phlebotomy is more effective than dietary iron reduction for 6 months, though a longer duration of dietary iron reduction will probably be able to decrease serum ferritin and ALT as well as phlebotomy. The median of percent change in ALT was -47.1% in treatment B group
Although the mechanism underlying hepatic iron overload in CHC remains unclear, hepatic excess iron must be originally derived from food. Normally, approximately 10 percent of 10 to 20 mg of iron ingested per day in an average diet is absorbed. This balances the daily obligatory losses of iron from the body that occur mainly from exfoliated gastrointestinal mucosal cells, with smaller amounts lost via the bile, urine, and skin. A recent report demonstrated that dietary iron loading exacerbated liver injury in HCV-infected chimpanzees without influencing viral load (13). Therefore, it is important for the prevention of hepatic iron overload to inhibit iron absorption from gastrointestinal (GI) tracts. The easiest method of reducing iron absorption is the restriction of dietary iron. The most interesting observation obtained in this trial was the fact that even dietary iron restriction significantly decreased serum ALT
